Latest Financial Performance News

Findi Ltd reports flat revenue and a 15% rise in EBITDA but swings to a $12.5 million net loss for FY2025, driven by strategic capital raises and refinancing in its Indian subsidiary.

NRW Holdings’ subsidiary Primero Group has landed a $157 million contract from Rio Tinto to deliver critical infrastructure at Hope Downs in Western Australia, extending their longstanding partnership.

Chorus Limited’s 2024 fibre regulatory report reveals a stable $5.9 billion asset base and revenue close to the maximum allowed, with a $153.5 million wash-up balance carried forward.

Pacific Edge Limited has launched a NZ$20 million capital raise to bolster its cash reserves amid the loss of Medicare coverage for its bladder cancer diagnostic tests, aiming to accelerate US market adoption and support new product development.

Hancock & Gore Limited reported a statutory net loss of $3.18 million for the half-year ended 31 March 2025, impacted by unrealised investment losses despite steady dividend income from its school uniform subsidiary. The company declared a fully franked interim dividend of 1 cent per share.

Vintage Energy has successfully completed a $2.1 million capital raise through fully subscribed Entitlement and Shortfall Offers, aiming to enhance gas output from its Cooper Basin fields.

ReadCloud Limited reports a robust first half FY25 with 13% organic revenue growth and a 73% jump in underlying EBITDA, powered by its expanding VET-in-Schools segment and disciplined cost management.

Elsight Limited has expanded its supply agreement with a European defence drone OEM to a total of US$9.63 million for 2025, positioning the company for profitability and cash flow break-even this year.

Mayfield Childcare Limited reports a significant operational and financial turnaround in Q2 FY25 under new CEO Daniel Stone, with improved earnings and cost efficiencies despite ongoing sector pressures.

Select Harvests Limited reported a robust half-year FY2025 profit, driven by a 37.6% jump in almond prices and strategic debt refinancing. Despite a slightly reduced crop volume, the company’s outlook remains positive amid strong global demand.

Aroa Biosurgery has reported FY25 results that exceed revenue guidance and deliver a positive normalised EBITDA, setting the stage for ambitious growth and reimbursement expansion in FY26.

Aroa Biosurgery has reported a robust 23% revenue increase in FY25, achieving profitability and positive cash flow, setting the stage for continued growth in FY26.